iConnectHub

Login/Register

WeChat

For more information, follow us on WeChat

Connect

For more information, contact us on WeChat

Email

You can contact us info@ringiertrade.com

Phone

Contact Us

86-21 6289-5533 x 269

Suggestions or Comments

86-20 2885 5256

Top

Real-time detection technology for M. tuberculosis launched

Source:Seegene Inc. Release Date:2012-08-03 292
Medical Equipment
Real-time test detects Mycobacterium tuberculosis and resistance mutations associated with MDR and XDR forms of M. tuberculosis

GAITHESBURG, MD – Seegene Inc., a multiplex molecular diagnostic technology developer, announced July 2, 2012 the introduction of Quantplex MTB/MDR/XDR Detection. The technology is a real-time test for the detection of Mycobacterium tuberculosis and resistance mutations associated with multiple drug resistant (MDR) and extensively drug resistant (XDR) forms of M. tuberculosis. The announcement was made at the 2012 American Association of Clinical Chemistry (AACC) annual meeting in Los Angeles.

The test is based on enhancements to the company’s TOCE technology, called Cleavage Site Specific Extension (TOCE-CSSE), enabling high multiplex mutation detection of disease. It is a first-in-class diagnostic test that can detect the presence of M. tuberculosis and determine if any of the eighteen rifampicin or seven isoniazid resistance mutations are present. The assay can also determine the presence of seven quinolone resistant mutations and six resistance mutations to injectable drugs.

"We have developed a low-cost and widely applicable real-time PCR assay for rapid detection of drug-resistant M. tuberculosis. This new method has been proven to be efficient and reliable in detecting a wide variety of mutations in clinical isolates. Cleavage Site Specific Extension is a natural extension and progression of the TOCE technology. The ability to detect and differentiate mutations -- point mutations, insertions and deletions -- is critical for the future of molecular diagnostics. The technologies that we are introducing today have the needs of tomorrow in mind. TOCE for mutation detection and differentiation will help empower molecular diagnostics to take the next steps towards personalized patient care," said Dr Jong-Yoon Chun, founder, CTO and CEO of Seegene.Zapatillas Trail Running
You May Like